About Us

Every Petsky Prunier engagement receives the highest level of attention from the senior members of our firm. Our leadership team includes a balance of accomplished former industry executives, experienced private equity investors, and career investment bankers. Together, we offer clients an unparalleled resource and distinguished track record of providing the highest standard of investment banking advice and strategic counsel.

Christopher French, Managing Director

Christopher French leads Petsky Prunier’s healthcare investment banking practice and has advised numerous HCIT, information, digital media and business services companies that support payers, providers, and life science companies. His practice has enjoyed strong recent success with fourteen completed transactions in the last thirty months. He also serves on the Board of Advisors of Crossix and USARx.

Prior to joining Petsky Prunier, Chris served as president and chief executive officer of Cadient Group, a private equity–backed digital agency for healthcare companies. Previously, he served in a number of leadership capacities — including senior vice president of global solutions marketing and corporate development — at Dendrite International, a publicly-traded provider of CRM software, information, and business services to the global life sciences industry. Prior to joining Dendrite, he was a corporate associate in the mergers and acquisitions practice at Skadden, Arps, Slate, Meagher & Flom, a leading global law firm.

Chris is a graduate of Fordham University School of Law and received a B.S. in economics from the Wharton School of the University of Pennsylvania.

Selected transactions led by Chris include:

  • Lucid's $60MM Series B minority investment led by North Bridge Growth Equity
  • VIIAD's Growth Investment from an Undisclosed Group of Investors
  • Sale of Pure Communications to W2O Group
  • Cognizant's acquisition of Idea Couture
  • Sale of BioPharm Communications to Omnicom Health Group
  • TotalMobile's Majority Investment from Lyceum Capital
  • Sale of MM Health Solutions to IMS Health
  • Sale of Healthcare Data Solutions to IMS Health
  • Sale of Cambridge BioMarketing to Everyday Health
  • $120MM Sale of MediMedia Pharma Solutions to ICON
  • Sale of Health Market Science to LexisNexis Risk Solutions
  • Sale of QualityHealth to Sharecare
  • $65MM Sale of DoctorDirectory to Everyday Health
  • Inspire's Growth Investment from Tenfore Holdings
  • Sale of Cadient Group to Cognizant
  • Sale of MediMedia Health's Sample Management Business to J. Knipper & Company
  • Sale of Ascribe to EMIS Group
  • Brand Networks' $68MM minority investment from AEA Investors
  • Sale of Alphadetail to ImpactRX a portfolio company of Symphony Technology Group
  • Sale of DentalPlans.com to The Riverside Company
  • Acquisition of ImpactRx by Symphony Technology Group
  • Sale of MediMedia Information Technologies to Susquehanna Growth Equity
  • Acquisition of Phoenix Marketing by MediMedia
  • Sale of TGaS to KnowledgePoint360 Group
  • Acquisition of Brulant by Rosetta
  • Majority Investment in Rosetta by Lindsay Goldberg
  • Sale of Infinata to Financial Times Group
  • Sale of Vogel-Farina to WPP
  • Acquisition of CorNet International by Dendrite
  • Acquisition of Analytika by Dendrite
  • Acquisition of Synavant by Dendrite
Back to Leadership Team